The Wall Street Journal reports that Congress members are pushing to transform the US FDA "by giving it broad powers to levy fines, order drug recalls and restrict drug-industry advertising," the article says. "The lawmakers say an FDA restructuring should build a much taller wall between the agency and the industry it regulates." The changes, if they happen, aren't expected to take place until next year.